OUR MISSION IS TO HELP MAKE SOMEDAY HAPPEN.

SOMEDAY DOCTORS WILL BE ABLE TO DIAGNOSE AND TREAT DEGENERATIVE BRAIN DISEASES BEFORE SYMPTOMS APPEAR.

SOMEDAY DOCTORS WILL BE ABLE TO DIAGNOSE AND TREAT DEGENERATIVE BRAIN DISEASES BEFORE SYMPTOMS APPEAR.

OUR MISSION IS TO HELP MAKE SOMEDAY HAPPEN.

The brain frontier
– –

Dopamine mediated brain disorders currently affect hundreds of millions of people worldwide. Dopamine deficiencies are associated with tremor, dementia, ADHD, schizophrenia, addiction and autism spectrum disorder.

When it comes to degenerative brain diseases like Parkinson’s, dementia and other dopamine transporter related diseases, early detection matters. These diseases can progress undetected for more than a decade before clinical symptoms appear. By then, the number of fully functional dopamine transporters in the brain may have declined significantly, leading to diseases like Parkinson’s and Lewy Body Dementia. Early, accurate detection is critical to developing and taking advantage of potential disease-modifying therapeutics.

LikeMinds’ mission is to provide a precise, early, accurate and therefore actionable diagnosis of Parkinson’s Disease, Lewy Body Dementia and other dopamine transporter related brain diseases using its dopamine transporter imaging agent, DaT2020.

The $1 Trillion Problem
– –

About 18 million Americans currently experience tremor and dementia symptoms that could be indicative of Parkinson’s disease or Lewy Body Dementia. Fueled by an aging demographic, this number is projected to grow to over 30 million Americans by 2050.

The McGovern Institute for Brain Research at MIT predicts that the annual cost of caring for people with tremor and dementia disorders will increase from $500 billion today to more than $1 Trillion by 2050 – Exceeding the cost of caring for Americans with heart disease and cancer combined[1].

The need for more accurate, timely and definitive diagnoses
– –

Diagnostic precision in imaging aids in the differential diagnosis and subsequent treatment of people with Parkinson’s disease and Essential Tremor. Charles Adler published in Neurology in July, 2014 that without precision brain imaging, clinical diagnosis error rates range from 50% – 74%, preventing physicians and scientists from having access to the early stage patients they need to test disease modifying treatment[2].

Actionable Insights
– –

Today, early, precise visualization of neuronal dopamine receptor activity is proving to be increasingly critical for actionable therapies for today’s early-stage tremor patients like Deep Brain Stimulation Surgery and/or MRI-guided High Intensity Focused Ultrasound. Tomorrow, dopamine transporter visualization and confirmation will enable early stage patients to be treated with disease modifying drugs that will prevent the onset of costly, debilitating symptoms.

Our mission
– –

To us, a patient’s tremor is the most recognizable outward sign of an underlying disease that began more than a decade before with an almost imperceptible dip in the patient’s dopamine transporter’s ability to function properly. Our approach to precision dopamine transporter imaging will give doctors the information they need to definitively detect, diagnose and manage each patient.

We are passionately focused on making precision brain imaging readily accessible to the doctors and scientists that need it to more effectively treat and eventually find cures for Parkinson’s and other dopamine transporter-related diseases.

[1] McGovern Institute for Brain Research at MIT
Brain Disorders: By The Numbers

[2] Neurology, 2014 Jul 29: 83(5) 406-412 Charles H. Adler et al
Low clinical diagnostic accuracy of early vs advanced Parkinson disease.

© 2017 LikeMinds | All Rights Reserved.